Director, Department of Liver Surgery, Fudan University Shanghai Cancer Center
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a single center, randomized, controlled study, to evaluate the efficacy and safety of Herombopag in patients with Thrombocytopenia before hepatectomy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 1\. Male and female subjects ≥18 years of age；
• 2.Patients prepared to receive hepatectomy；
• 3.50×10\^9/L≤platelet count≤80×10\^9/L；
• 4.Child-PUgh score A or grade B (≤7 )；
• 5.Life expectancy ≥3 months；
• 6.Normal Bone marrow hematopoiesis and renal function;
• 7.Voluntary participation and written informed consent;
Locations
Other Locations
China
Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Contact Information
Primary
Lu Wang, Professor
wang.lu99@hotmail.com
18121299555
Backup
Ti Zhang, Professor
zhangti@shca.org.cn
15800680751
Time Frame
Start Date: 2022-07-25
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 96
Treatments
Experimental: Experimental: 1
durg：Hetrombopag 5mg，once daily，oral
Experimental: Experimental: 2
Ndurg： Placebo 5mg，once daily，oral
Related Therapeutic Areas
Sponsors
Leads: Fudan University